Clinical Trial Update: Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Centre Leon Berard | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED